-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride Cr in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride Cr in Irritable Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ondansetron Hydrochloride Cr in Irritable Bowel Syndrome Drug Details:Ondansetron hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Doxycycline Hyclate Cr in Surgical Wound Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Doxycycline Hyclate Cr in Surgical Wound Infections Drug Details: Doxycycline hyclate is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resiquimod in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resiquimod in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Resiquimod in Non Muscle...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KT-413 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KT-413 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KT-413 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: KT-413 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CyPep-1 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CyPep-1 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CyPep-1 in Melanoma Drug Details:CyPep-1 is under development for the treatment of cutaneous warts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-2029 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-2029 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CX-2029 in Solid Tumor Drug Details: CX-2029 is under development for the...
-
Sector Analysis
Malaysia Cards and Payments – Opportunities and Risks to 2027
Malaysia Cards and Payments Market Report Overview The annual value of card transactions in the Malaysia cards and payments market is estimated to be $84.5 billion in 2023 and is expected to grow at a CAGR of more than 10% during 2023-2027. The Malaysian payments market remains cash-reliant but has high growth potential as it shifts towards digital payments. Government initiatives including the introduction of an interchange fee cap, the migration of payment cards to support contactless payments, charges on...
-
Analyst Opinions
Asia-Pacific Regional Retail Banking Analysis by Consumer Credit, Retail Deposits and Residential Mortgages
Asia-Pacific (APAC) Regional Retail Banking Analysis Report Overview GDPs across the APAC region is likely to continue growing, with India, Vietnam, and the Philippines experiencing the fastest growth. However, there is notable GDP variation across the region, with China having a significantly higher GDP than New Zealand. Inflation rates post-COVID-19 are expected to level off, although food and oil prices are set to remain high as the Russia/Ukraine conflict continues to affect India and other major exporters. India has the highest...
-
Company Profile
RHB Bank Bhd – Company Profile
RHB Bank Bhd (RHB) is a provider of integrated financial services that include retail banking, business transaction banking, wholesale banking, insurance, and Sharia banking. Its offerings comprise commercial banking and finance-related business, investment banking, Islamic banking, stockbroking, leasing, and offshore banking. RHB also offers property investment, offshore trust services, general insurance, unit trust administration, nominee and custodian services, and asset management. The bank through a network of branch offices, ATMs, and online portals caters to retail, commercial, SME, high net-worth...
Add to Basket -
Product Insights
Net Present Value Model: RHB-104
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model RHB-104 Drug Details RHB-104, a fixed...